CANTEX

Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Biological testing and research in the field of pharmaceuticals; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases

Providing medical and scientific research information about the diagnosis and treatment of diseases, namely, infectious diseases, viral diseases, and autoimmune diseases; Providing information in the fields of health, wellness, and pharmaceuticals via a website; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses

Licensing of pharmaceuticals and drug discovery technologies